Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that …